Treatment with All-trans Retinoic Acid Plus Tamoxifen and Vitamin E in Advanced Hepatocellular Carcinoma

Anticancer Research

Volumn 24, Issue 2 C, 2004, Pages 1255-1260

  Clerici, Carlo ^a   Castellani, Danilo ^a   Russo, Giuseppe ^a   Fiorucci, Stefano ^a   Sabatino, Giuseppe ^a   Giuliano, Vittorio ^a   Gentili, Giorgio ^a   Morelli, Olivia ^a   Raffo, Patrizia ^b   Baldoni, Monia ^a   Morelli, Antonio ^a   Toma, Salvatore ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

Hepatocellular carcinoma; RAR receptors; Retinoic acid; Tamoxifen

Indexed keywords

ALPHA TOCOPHEROL; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; RETINOIC ACID RECEPTOR BETA; RETINOIC ACID RECEPTOR GAMMA; RETINOID X RECEPTOR ALPHA; TAMOXIFEN CITRATE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG EFFECT; DRUG EFFICACY; EVALUATION; FEMALE; GENERAL CONDITION IMPROVEMENT; HEADACHE; HUMAN; ITALY; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FUNCTION; MALE; PAIN; PILOT STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; TUMOR VOLUME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PILOT PROJECTS; TAMOXIFEN; TRETINOIN; VITAMIN E;

EID: 2442466979     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. WHO. Prevention of Liver Cancer. WHO Techincal Report series. WHO, Geneva, 1983.
2. Biscaeglie AM, Rustgi VK, Hoofnagle JH et al: Hepatocellular carcinoma. Ann Intern Afed 108: 390, 1988.
3. London WT: Primary hepatocellular carcinoma - etiology pathogenesis and prevention. Human Path 12: 1085, 1981.
4. Lai CL, Lam KC, Wong KP, Wu PC and Todd D: Clinical features of hepatocellular carcinoma: review of 211 patients in Hong Kong. Cancer 47: 2746-2755, 1981.
5. Okuda K, Ohtsuki T, Obata H, Tominatsu M, Okazaki N, Hasegawa H et al: Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Cancer 56: 918-928, 1985.
6. The Cancer of the Liver Italian Program (CLIP) Investigation. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 31(4): 840-845, 2000.
7. Lai CL, Wu PC, Chan GC, Lok AS and Lin HJ: Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 62(3): 479-83, 1988.
8. Groupe d'etude et de traitment du carcinome hépatocellulaire: A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 332: 1256-1261, 1995.
9. Porter LE, Elm MS, Van Thiel DH, Dugas MC and Eagon PK: Characterization and quantitation of human hepatic estrogen receptor. Gastroenterology 84: 704-712, 1983.
10. Rossini GP, Baldini GM, Villa E and Manenti F: Characterization of estrogen receptor from human liver. Gastroenterology 96: 1102-1109, 1989.
11. Francavilla A, Di Leo A, Eagon PK, Wu SQ, Ove P, Van Thiel DH et al: Regenerating rat liver: correlation between estrogen receptor localization and dehoxyribonucleic acid synthesis. Gastroenterology 86: 562-567, 1984.
12. Kim DG, Jo BH, You KR and Ahn DS: Apoptosis induced by retinoic acid in Hep 3B cells in vitro. Cancer Lett 107: 149-159, 1996.
13. Hsu SL, Lin HM and Chou CK: Suppression of the tumorigenicity of human hepatoma Hep3B cells by long-term retinoic acid treatment. Cancer Lett 99: 79-85, 1996.
14. Daoud AH and Griffin AC: Effect of retinoic acid, butylated-hydroxytoluene, selenium and ascorbic acid on azo dye hepatocarcinogenesis. Cancer Lett 9: 299-304, 1980.
15. Maiorana A and Gullino PM: Effect of retinyl acetate on the incidence of mammary carcinomas and hepatomas in mice. J Natl Cancer Inst 64: 655-663, 1980.
16. Yu MW, Hsieh HH, Pan WH, Yang CS and CHen CJ: Vegetable consumption, serum retinol level, and risk of hepatocellular carcinoma. Cancer Res 55: 1301-1305, 1955.
17. Rocchi E, Seium Y, Camellini L, Casalgrandi G, Borghi. A, D'Alimonte P et al: Hepatic tocopherol content in primary hepatocellular carcinoma and liver metastases. Hepatology 26: 67-72, 1997.
18. Yasutoshi M, Hisattaka M, Mitsuo N et al: Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl J Med 334: 1561-1567, 1996.
19. Toma S, Raffo P and Isnardi L: Association of retinoids, tamoxifene and alpha-interferon 2a in human breast cancer: in vitro and in vivo studies. Int J Oncol 10: 597-607, 1997.
20. Herold C, Ganslmayer M, Ocker M, Hermann M, Hahn EG and Schuppan D: Combined in vitro anti-tumoral action of tamoxifen and retinoic acid derivatives in hepatoma cells: Int J Oncol 20: 89-96, 2002.
21. Ohnhaus EE and Adler R: Methodological problems in the measurement of pain: a comparison between the verbal rating scale and the visual analogue scale. Pain 1: 379-384, 1975.
22. Frickel F: Chemistry and physical roperties of retinoids. In: The Retinoids, vol.2, eds. Sporn MB, Roberts AB, Goodman DS. Academic Press, San Diego 1984, pp 8-145.
23. Guenther R, Fuerst M, Nasser S, Bauer I, Schmidt WE and Foelsch UR: All-trans-retinoic acid induced apoptosis in HepGZ cells is mediated by Jun-N-terminal kinase (JNK) activation. Hepatology 36: 468A, 2002.
24. Jinushi M, Takehara T, Tatsumi T, Miyagi T, Suzuki T, Kanto T et al: MHC class I-like MICA/B are expressed on human hepatocellular carcinoma and their up-regulation by retinoic acid induces enhanced natural killer cell-mediated immune responses. Hepatology 36: 434A, 2002.
25. Mangelsdorf DJ and Evans RM: The RXR heterodimers and orphan receptors. Cell 83: 841-850, 1995.
26. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K et al: The nuclear receptor superfamily: the second decade. Cell 83: 835-839, 1995.
27. Chiang JY: Bile acid regulation of gene expression: roles of nuclear hormone receptors. Endocr Rev 23: 443-463, 2002.
28. Plass JR, Mol O, Heegsma J, Geuken M, Faber KN, Jansen PL and Muller M: Farnesoid X receptor and bile salts are involved in transcriptional regulation of the gene encoding the human bile salt export pump. Hepatology 35: 589-596, 2002.
29. Chow PK, Tai BC, Tan CK, Machin D, Win KM, Johnson PJ and Soo KC: High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial. Hepatology 36: 1221-1226, 2002.
30. Lin DY, Lin SM and Liaw YF: Non-surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 12: S319-S328, 1997.
31. Simonetti RG, Liberati A, Angiolini C and Pagliaro L: Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol 8: 117-136, 1997.
32. Roila F and Cortesi E: Quality of life as a primary end point in oncology. Ann Oncol 12: S3-S6, 2000.
33. Sun SY, Wan H, Yue P, Hong WK and Lotan R: Evidence that retinoic acid receptor beta induction by retinoids is important for tumor cell growth inhibition. JBC 275: 17149-17152, 2000.
34. Sirchia SM, Ren M, Pili R, Sironi E, Somenzi G, Guidoni R, Toma S, Nicolo G and Sacchi N: Endogenous reactivation of the RAR beta 2 tumour suppressor gene epigenetically silenced in breast cancer. Cancer Res 62: 2455-2461, 2002.
35. Primeau M, Gagnon J and Momparler RL: Synergistic antineoplastic action of DNA methylation in inhibitor 5-aza-2 deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells. Int J Cancer 103: 177-184, 2003.